Ascentage Pharma Group International is a global commercial stage biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. For more than two decades, the founders and team have leveraged deep expertise in chemistry and biology to develop a proprietary drug discovery platform focused on particularly challenging targets and significant unmet global medical needs. The company's lead assets include Olverembatinib, a novel third-generation tyrosine kinase inhibitor targeting BCR-ABL1 and related kinases, and Lisaftoclax, a novel Bcl-2 inhibitor designed to restore apoptosis in cancer cells. These assets address major hematological malignancies such as chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, and myelodysplastic syndrome. Ascentage Pharma Group International's approach centers on modulating key apoptotic pathways and tyrosine kinase signaling to develop therapies for conditions with high unmet medical need.
Ascentage Pharma Group International generates revenue primarily through commercial sales of its approved therapeutic products. Olverembatinib received approval in China for chronic myeloid leukemia with specific resistance profiles and is now commercialized there, with all indications included in the National Drug Reimbursement List effective January 2025. Lisaftoclax gained approval in China in July 2025 for chronic lymphocytic leukemia and small lymphocytic lymphoma in patients previously treated with at least one systemic therapy including BTK inhibitors, and commercial sales commenced shortly after receiving regulatory clearance. Revenue is derived from product sales in authorized markets, with China serving as a primary commercial territory due to national reimbursement coverage and established distribution networks. Additionally, the company earns revenue through strategic partnerships, including upfront payments, milestone achievements, and royalties from agreements with firms such as Innovent for Olverembatinib development and commercialization, and from equity transactions like the share sale to Takeda in June 2024.
Ascentage Pharma Group International positions itself as a differentiated integrated biopharmaceutical company in the global hematological malignancies market. The company targets a market estimated at $67.2 billion in 2023 and projected to grow to $208.8 billion by 2035 according to third-party reports. It faces competition from established players including Novartis (marketing asciminib) and Takeda (marketing ponatinib) for BCR-ABL1 targeted therapies, and AbbVie (marketing venetoclax) for Bcl-2 inhibitors. Key competitive advantages stem from vertical integration: a 200,000 square foot manufacturing facility capable of producing up to 250 million dosage units annually supporting both clinical trials and commercial supply; a discovery team with deep expertise in small molecule chemistry and targeted protein degradation; an integrated clinical development team managing trials across China, the United States, the United Kingdom, and Australia; and a commercial organization exceeding 270 dedicated members in China complemented by U. S.-based leadership with global oncology experience. The dual lead assets Olverembatinib and Lisaftoclax are in advanced development, collectively addressing all five major hematological malignancies through multiple late-stage clinical trials. The company's proprietary platform enables development of inhibitors and degraders against targets including Bcl-2, Bcl-2/Bcl-xL, IAP, MDM2, and epigenetic modifiers like EZH2. It emphasizes being the sole entity with active clinical programs targeting all three known classes of apoptosis regulators as cited in industry analyses. As of December 31, 2025, the global team numbered approximately 767 employees with 447 engaged in research and development activities, supporting a pipeline of seven clinical-stage candidates.
Ascentage Pharma Group International serves patients diagnosed with hematological malignancies through healthcare providers and institutional settings. The company's commercialized products Olverembatinib and Lisaftoclax are distributed to hospitals and retail pharmacies where they are dispensed to eligible patients following physician prescription. In 2025, the commercial team reported coverage of more than 1,500 hospitals and over 800 pharmacies for these two approved products. Strategic alliances with leading pharmaceutical distributors ensure nationwide drug distribution coverage in key operational regions. The company collaborates with major pharmaceutical distributors to maintain reliable supply chains. The customer base encompasses healthcare systems treating conditions such as chronic myeloid leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and related blood cancers. Furthermore, Ascentage Pharma Group International engages in scientific collaborations with biotechnology and pharmaceutical leaders including Innovent for Olverembatinib, and clinical partnerships with AstraZeneca, Merck, and Pfizer, alongside research ties to institutions like Dana-Farber Cancer Institute, Mayo Clinic, MD Anderson Cancer Center, National Cancer Institute, and the University of Michigan to advance its therapeutic pipeline and clinical development efforts.